Iftekhar Ahmed
Neurology · Kansas City, MONPI 1932286937
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2019 at $1,015 and has fallen 95.7% since, to $43 in 2024.
Across 183 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$763
- Sanofi$317
- Avanir Pharmaceuticals, Inc.$299
- Amgen$226
- Novartis$226
- Bristol Myers Squibb$165
- plus $742 from 20 others
What the payments were for
- Speaking & faculty fees$863%
- Food & beverage$2,65197%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $763 |
| Sanofi | 16 | $317 |
| Avanir Pharmaceuticals, Inc. | 42 | $299 |
| Amgen | 10 | $226 |
| Novartis | 16 | $226 |
| Bristol Myers Squibb | 12 | $165 |
| Abbott | 4 | $95 |
| Acorda Therapeutics, Inc | 4 | $86 |
| Jazz Pharmaceuticals Inc. | 1 | $64 |
| CSL Behring | 3 | $64 |
| Amneal Pharmaceuticals LLC | 3 | $60 |
| Eisai Inc. | 3 | $50 |
| Boston Scientific | 4 | $48 |
| Argenx US, Inc. | 2 | $44 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Grifols USA, LLC | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Bio Products Laboratory USA, Inc. | 1 | $20 |
| Urovant Sciences Inc | 1 | $17 |
| Biogen | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Medtronic | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| UCB, Inc. | 1 | $13 |
How this compares
$2,737 in reported general payments places this provider in the 65th percentile of 381 neurology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 49 | $1,315 |
| Lacosamide | 11 | $877 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 19 | $829 |
| Gabapentin | 27 | $456 |
| Primidone | 31 | $377 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 38 | $341 |
| Lamotrigine | 12 | $285 |
| Topiramate | 24 | $282 |
| Memantine Hcl | 15 | $247 |
| Donepezil Hcl | 28 | $186 |
| Ropinirole Hcl | 11 | $147 |
Paid to pharmacies, not to this prescriber.
Other neurology in Kansas City
- Stanley FisherKansas City$155K
- Rola MahmoudKansas City$155K
- Robert ReddigKansas City$129K
- Samuel GoldlustKansas City$124K
- Brooke HeffernanKansas City$27K
- Susan SifersKansas City$25K
- William RosenfeldChesterfield$2.1M
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.